The European Patent Office intends to grant Brighter a patent for the use of a proximity sensor to log insulin injections in Actiste.
Brighter's patent for the use of a proximity sensor to log insulin injections will be granted by the European Patent Office. The proximity sensor automatically disregards any fluid released from the injector during priming, so this is not registered as an injected dose. The patent is not limited to insulin and applies to use of this function in many injection devices with any pharmaceutical, to disregard priming.
It is recommended to prime the injector in order to remove air bubbles from the needle to ensure full dose administration. The sensor that registers data on the actual injected insulin dose aims to also enable caregivers to provide a more adequate individualized treatment.
"I am very pleased that this patent will be granted. For patient safety reasons, it is incredibly important that injection devices work correctly and reliably. This patent is indicative of the value of Brighter’s innovative IP, and its potential applicability to other markets,” says Christer Trägårdh, interim CEO of Brighter AB.
For further information, please contact:
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, firstname.lastname@example.org, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research.Brighters kvalitetsledningsystem är ISO-13485-certifierat. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.